Piper Sandler Confident in Oscar Health's (OSCR) Market Share and Profitability Growth, Sets $404M Minimum 2027 Adjusted EBITDA Expectation

Oscar Health Inc. (NYSE:OSCR) is one of the high short interest stocks to buy right now. On November 26, Piper Sandler analyst Jessica Tassan upgraded Oscar Health to Overweight from Neutral with a $25 price target, raised from $13. After a thorough analysis of benefit design, pricing, and broker strategy in Miami-Dade, which is Oscar’s largest county, Tassan believes that Oscar can simultaneously increase market share and profitability, even if the Enhanced Advance Premium Tax Credits/E-APTCs expire at the end of 2025. Piper Sandler views Oscar’s 2027 adjusted EBITDA of $404 million as the minimum expectation.

In its Q3 2025 earnings call, reported earlier the same month, Oscar Health announced a 23% year-over-year increase in total revenue, which reached ~$3 billion. Oscar also reported a strong increase in membership, ending the first 9 months of 2025 with more than 2 million members, which represents a 28% increase compared to the previous year. To enhance its market presence, Oscar Experience is now available in 20 states, including new entries into Alabama and Mississippi.

Additionally, the company is introducing innovative products, such as the Hello Meow plan for women experiencing menopause, and is using its health AI agent, called Oswell, to improve member health management and care paths. Looking ahead, Oscar Health anticipates a contraction in the overall market due to the expected expiration of enhanced premium tax credits and ongoing program integrity efforts. Consequently, the company expects a sequential decline in membership in Q4 due to historical churn patterns and the end of continuous monthly Special Enrollment Periods/SEP for certain income levels.

Oscar Health Inc. (NYSE:OSCR) operates as a healthcare technology company in the US. The company offers health plans to individuals, families, employees, and small group markets.

While we acknowledge the potential of OSCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.